Suppr超能文献

结核分枝杆菌抗原5在结核菌素阳性人类受试者中的初步临床试验。

Initial clinical trial of Mycobacterium tuberculosis antigen 5 in tuberculin-positive human subjects.

作者信息

Daniel T M, Van der Kuyp F, Anderson P A

出版信息

Am Rev Respir Dis. 1981 May;123(5):517-20. doi: 10.1164/arrd.1981.123.5.517.

Abstract

A single lot of Mycobacterium tuberculosis antigen 5 was used in graded doses to skin test 92 persons in a geographic area where nonspecific tuberculin reactivity is uncommon. In 47 tuberculin-positive subjects, antigen 5 was found to have a potency of 2.7 tuberculin units/micrograms. An intradermal dose of 0.50 microgram was found to give typical delayed skin test reactions in all of 15 tuberculin-positive subjects, with a mean reaction size of 15.17 mm. Some preparations of antigen 5 were found to be unstable during lyophilization and storage; solutions of antigen 5 in diluent containing Tween 80 were stable. Mycobacterium tuberculosis antigen 5 is a potent tuberculin skin test antigen deserving of further clinical evaluation.

摘要

使用一批结核分枝杆菌抗原5的分级剂量对一个非特异性结核菌素反应不常见地理区域的92人进行皮肤试验。在47名结核菌素阳性受试者中,发现抗原5的效价为2.7结核菌素单位/微克。发现皮内注射0.50微克剂量能使所有15名结核菌素阳性受试者产生典型的迟发性皮肤试验反应,平均反应大小为15.17毫米。发现一些抗原5制剂在冻干和储存过程中不稳定;抗原5在含有吐温80的稀释剂中的溶液是稳定的。结核分枝杆菌抗原5是一种有效的结核菌素皮肤试验抗原,值得进一步进行临床评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验